Stock analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The company has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
About Genocea Biosciences
See Also
- Five stocks we like better than Genocea Biosciences
- What is a Bond Market Holiday? How to Invest and Trade
- Hasbro’s Management Made All the Right Calls This Quarter
- 3 Best Fintech Stocks for a Portfolio Boost
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Are Penny Stocks a Good Fit for Your Portfolio?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.